News

Latest News:

mc2_news-image-icon-04

MC2 Therapeutics Announces Positive Top-line Results from EU Phase 3 Head-to-Head trial Comparing Wynzora™ Cream to Daivobet® Gel in Patients with Psoriasis

POSTED: December 18, 2019

  • Wynzora™ Cream demonstrates statistically significantly better treatment efficacy compared to Daivobet® Gel.
  • Wynzora™ Cream demonstrates statistically significantly better treatment convenience and quality of life measures compared to Daivobet® Gel.
  • Submission of Marketing ...

    READ FULL ARTICLE >

MC2 Therapeutics Announces FDA Acceptance of its New Drug Application for Wynzora™ Cream for Treatment of Plaque Psoriasis

POSTED: November 20, 2019

Copenhagen, November 20th, 2019 – MC2 Therapeutics, an emerging pharmaceutical company focused on novel PAD™ Technology-based topical therapies for chronic inflammatory conditions, today announced that the U.S. Food and Drug ...

READ FULL ARTICLE >

mc2_news-image-icon-04

MC2 Therapeutics Announces Submission of New Drug Application to US FDA for Wynzora™ Cream (Calcipotriene 0.005% and Betamethasone Dipropionate 0.064%) for Treatment of Plaque Psoriasis

POSTED: September 24, 2019

Copenhagen, September 24th, 2019 – MC2 Therapeutics, a late clinical-stage pharmaceutical company focused on novel PAD™ Technology-based topical therapies for chronic inflammatory conditions, today announced that it has submitted a ...

READ FULL ARTICLE >

mc2_news-image-icon-07

MC2 Therapeutics A/S Completes Enrollment of EU Phase 3 Head-to-Head Study in Patients with Plaque Psoriasis Treated with MC2-01 PAD TM Cream

POSTED: August 7, 2019

  • Topline data are expected in Q4 2019

Copenhagen, August 7th, 2019 – MC2 Therapeutics A/S, a late clinical-stage pharmaceutical company focused on topical therapies for chronic inflammatory conditions, today announced the ...

READ FULL ARTICLE >

MC2 Therapeutics A/S appoints Samia Kappe as Executive Vice President Sales & Marketing Europe

POSTED: April 4, 2019

Copenhagen, April 4th, 2019 – MC2 Therapeutics A/S, a late clinical-stage company focused on topical therapies for chronic inflammatory conditions, today announced the appointment of Samia Kappe as Executive Vice ...

READ FULL ARTICLE >

mc2_news-image-icon-04

MC2 Therapeutics A/S announces first patient dosed in EU Phase 3 trial in psoriasis vulgaris

POSTED: January 6, 2019

  • First patient dosed in Phase 3 trial assessing the safety and efficacy of MC2-01  Cream in EU
  •  Topline results are expected in Q3 2019

Copenhagen, January 6th, 2019 – MC2 Therapeutics A/S, ...

READ FULL ARTICLE >

Upcoming Events:

There are no upcoming events at the moment.

READ MORE >

© mc2 therapeutics 2020